Global Partners LP(GLP)Earnings, Financials & Key RatiosGlobal Partners LP (GLP) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
while the 8.0% dividend yield is attractive, the company's erratic free cash flow and a debt-to-EBITDA ratio that reached 31.26 in 2025Q4 suggest significant risks to capital preservation.
Global Partners LP (GLP) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Global Partners LP (GLP) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $1.85vs $0.33+460.6% | $5.3Bvs $7.0B-23.7% |
| Q1 2026 | Feb 27, 2026 | $0.54vs $0.60-10.0% | $4.6Bvs $6.9B-33.0% |
| Q4 2025 | Nov 7, 2025 | $0.66vs $1.09-39.4% | $4.7Bvs $6.9B-32.3% |
| Q3 2025 | Aug 7, 2025 | $0.55vs $0.60-8.3% | $4.6Bvs $6.5B-28.4% |
Recent stock market news and headlines for Global Partners LP (GLP)
Eli Lilly's growth rate has been accelerating over the past year due to its GLP-1 drugs. The recent approval of its GLP-1 pill, Foundayo, could offer yet another catalyst.
Kailera Therapeutics said on Tuesday its GLP-1 drug for patients with diabetes and obesity met the main goal of two-late stage trials.
Nestle is looking to spice up some of its products to counter duller taste buds that can accompany GLP-1 weight-loss drugs.
Lower crude prices have reset energy-sector expectations, making GLP, NESR and IMO buy candidates for investors seeking oil-linked opportunities.
Vancouver, British Columbia--(Newsfile Corp. - July 6, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company") announces it has entered into an agreement with Nucro-Technics Inc. ("Nucro") to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD.
Key metrics vs top competitors for Global Partners LP (GLP)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $48.47 | $1.65B | 22.97 | 8.14% | 0.43% | 11.38% | 7.64% | |
| $22.57 | $860.71M | 20.71 | -10.63% | 2.03% | — | — | |
| $2.34 | $91.39M | -6.32 | 1.2% | -2.84% | — | — | |
| $15.42 | $1.92B | -4.42 | -9.02% | -5.71% | -39.5% | — | |
| $67.79 | $9.26B | 18.52 | 11.05% | 2.72% | 12.87% | — | |
| $73.94 | $13.33B | 23.77 | -5.99% | 4.46% | 13.02% | — |
Global Partners LP (GLP) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Global Partners LP (GLP) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 8, 2026·SEC
Apr 30, 2026·SEC
Apr 13, 2026·SEC
Get notified when GLP posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Global Partners LP (GLP) stock FAQ — growth, dividends, profitability & financials explained
Global Partners LP (GLP) reported $19.29B in revenue for fiscal year 2025. This represents a 1000% increase from $1.75B in 2001.
Global Partners LP (GLP) grew revenue by 8.1% over the past year. This is steady growth.
Yes, Global Partners LP (GLP) is profitable, generating $129.7M in net income for fiscal year 2025 (0.4% net margin).
Yes, Global Partners LP (GLP) pays a dividend with a yield of 7.64%. This makes it attractive for income-focused investors.
Global Partners LP (GLP) has a return on equity (ROE) of 11.4%. This is reasonable for most industries.
Global Partners LP (GLP) generated $155.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
